The FDA has released three new guidance documents on cell and gene therapy development, covering clinical trial design and ...
Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) ...
Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced an upcoming ...
Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.
Ginkgo Bioworks Holdings has maintained its fair value price target at $12.00 per share, with only slight shifts in the underlying assessment from market analysts. The minor increase in the discount ...
ChemDiv today announced the extension of its discovery and early development partnership with Mondego Bio to advance the company's best-in-class immuno-oncology program targeting PTPN2. The ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
The Vivo X300 and X300 Pro have gradually been certified in different countries. The latest development is that the Vivo X300 and X300 Pro have received approval from India’s BIS authority, indicating ...
There’s something poetic about the way Vivo is trying to talk about software these days. For years, Vivo built hardware that ...
Kenya’s grassroots motorsport is back on track thanks to the 2025 Shell Autocross and Autocross Plus Championship, now run by ...
The operating margin of 5.6% means that on a R200 000 vehicle, WeBuyCars makes, on average, R11 200. On a R300 000 vehicle, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback